Previous studies also indicated that intra-tumoral TLSs predicted a better response to immunotherapy independent of PD-L1 expression status and CD8+ T cell density, not only for ICC, but also for other types of solid tumors including hepatocellular carcinoma and melanoma [4, 25–28]. The gene discussed is CD8A; the disease is melanoma.